Shanx Medtech BV raised €15 million (US$17.5 million) in a seed funding round for its in vitro diagnostic platform for ultra-rapid antimicrobial susceptibility testing. The financing came from a range ...

What antibiotic should I use to treat this patient’s Klebsiella pneumoniae? It’s resistant to carbapenems, and there’s a ...

The International Space Station (ISS) is a closed ecosystem, and the biology inside it — including its microbial residents — ...

Ranchi: Districts with lower reporting of presumptive tuberculosis (TB) cases were on Wednesday asked to intensify screening ...

Infection with the pathogenic yeast fungus Candida auris (C. auris) can wreak havoc on the health of hospital patients and ...

Chronic lung infections pose a disproportionate threat to older adults, yet the biological mechanisms behind age-specific ...

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea has announced a reshaping of its US commercial leadership, with VP US ...

Bacterial Conjunctivitis Drugs Market is expected to reach US$ 4.9 Billion by 2036, Driven by Increasing Prevalence of Eye ...

Women under 50, even those who don’t smoke, are seeing a rise in lung cancer cases. Oncologist stresses recognising warning ...

The funding will support final development, clinical validation, regulatory approval, and commercial launch of an ultra-rapid AST platform.

Some antibiotics stop bacteria from growing without actually killing them, allowing infections to return later. Scientists at ...